Clinical trials: Arthritis,Rheumatoid
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01326962
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Taiwan.
- Trial name
- ROCKI (NCT02616380)
- Volunteers
- 100 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy.
- Trial name
- NCT01543503
- Where
- 154 sites in Argentina, Belgium and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
Arthritis, Rheumatoid
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and…
- Trial name
- NCT01645280
- Testing
- Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4)
- Where
- 47 sites in United States, Argentina and 9 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.
- Trial name
- NCT01890473
- Testing
- Abatacept
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
This single arm study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced an inadequate response.
- Trial name
- NCT00424502
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- 3 sites in Hungary
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis.
- Trial name
- NCT01393639
- Testing
- PF-04171327, prednisone
- Where
- 93 sites in United States, Bulgaria and 16 more
- Volunteers
- 323 people
- Sponsor
- Pfizer
Osteoarthritis, Hip, Fracture of Hip
Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System
This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2.
- Conditions
- Osteoarthritis, Hip, Fracture of Hip, Avascular Necrosis of Hip, Dislocated Hip
- Trial name
- NCT04079114
- Testing
- Patients who received the Stafit Acetabular System
- Volunteers
- 166 people
- Sponsor
- Zimmer Biomet
Arthritis, Rheumatoid Arthritis
Wright Foot & Ankle Post-Market Observational Study
WRIGHT FOOT \& ANKLE POST-MARKET OBSERVATIONAL STUDY, Multi-Year, Multi-Site, Multi-Device, Post-Market Observational Study, 10 sites, a minimum of 40 patients per device
- Conditions
- Arthritis, Rheumatoid Arthritis, Fracture, Trauma Injury
- Trial name
- NCT04118894
- Testing
- Foot and Ankle Devices
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Stryker Trauma and Extremities
Rheumatoid Arthritis
GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
The study objective is to identify potential safety risks of the transition from US-licensed Rituxan® or EU-approved MabThera® to GP2013 (proposed biosimilar product) as compared to continuous treatment with the originator…
- Trial name
- ASSIST-RT (NCT02514772)
- Testing
- GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
- Where
- 65 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Sandoz
Rheumatoid Arthritis
Observational Trial With Enbrel
The diagnosis, evaluation and treatment of rheumatoid arthritis (RA) continue to undergo rapid change. Randomized controlled trials such as the TEMPO study have demonstrated the efficacy and safety of the combination of…
- Trial name
- NCT00488475
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 4,945 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis.
- Trial name
- NCT01705730
- Testing
- tocilizumab
- Where
- 17 sites in Belgium
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
The purpose of this study is to evaluate clinical effectiveness and safety of golimumab with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) when compared to MTX alone.
- Trial name
- NCT00973479
- Testing
- Golimumab, methotrexate (MTX)
- Where
- 88 sites in United States, Argentina and 11 more
- Volunteers
- 592 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to…
- Trial name
- ROSE (NCT00531817)
- Testing
- Tocilizumab, Permitted DMARDs
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16.
- Trial name
- DoseFlex (NCT00580840)
- Testing
- Certolizumab pegol
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 333 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat…
- Trial name
- RATE-RA (NCT01382940)
- Testing
- rituximab, methotrexate, methylprednisolone
- Where
- 86 sites in United States
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
NSAID-induced Gastroduodenal Injury, Ulcers
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
- Conditions
- NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00597818
- Testing
- Cobiprostone, Non-steroidal anti-inflammatory drug
- Where
- 19 sites in United States
- Volunteers
- 121 people
- Sponsor
- Sucampo Pharma Americas, LLC
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT01000610
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 4 sites in Tunisia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
- Trial name
- ANTIBODY-RA (NCT01981473)
- Testing
- no intervention
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 605 people
- Sponsor
- Pfizer